

EMA/439197/2019

## European Medicines Agency decision P/0333/2019

of 11 September 2019

on the acceptance of a modification of an agreed paediatric investigation plan for pazopanib (Votrient), (EMA-000601-PIP01-09-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

# European Medicines Agency decision

P/0333/2019

of 11 September 2019

on the acceptance of a modification of an agreed paediatric investigation plan for pazopanib (Votrient), (EMA-000601-PIP01-09-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the European Medicines Agency's decision P/4/2011 issued on 3 January 2011, the decision P/0191/2012 issued on 24 August 2012, the decision P/0132/2014 issued on 10 June 2014, the decision P/0061/2016 issued on 18 March 2016, the decision P/0163/2017 issued on 30 June 2017 and the decision P/0405/2018 issued on 20 December 2018,

Having regard to the application submitted by Novartis Europharm Limited on 16 April 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 July 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for pazopanib (Votrient), film-coated tablet, age-appropriate oral formulation, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

**Article 2**

This decision is addressed to Novartis Europharm Limited, Vista Building Elm Park, Merrion Road, 4 – Dublin, Ireland.

EMA/PDCO/260997/2019  
Amsterdam, 26 July 2019

## Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000601-PIP01-09-M06

### Scope of the application

**Active substance(s):**

Pazopanib

**Invented name:**

Votrient

**Condition(s):**

Treatment of rhabdomyosarcoma

Treatment of non-rhabdomyosarcoma soft tissue sarcoma

Treatment of Ewing sarcoma family of tumours

**Authorised indication(s):**

See Annex II

**Pharmaceutical form(s):**

Film-coated tablet

Age-appropriate oral formulation

**Route(s) of administration:**

Oral use

**Name/corporate name of the PIP applicant:**

Novartis Europharm Limited

**Information about the authorised medicinal product:**

See Annex II

## Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted to the European Medicines Agency on 16 April 2019 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/4/2011 issued on 3 January 2011, the decision P/0191/2012 issued on 24 August 2012, the decision P/0132/2014 issued on 10 June 2014, the decision P/0061/2016 issued on 18 March 2016, the decision P/0163/2017 issued on 30 June 2017 and the decision P/0405/2018 issued on 20 December 2018.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 28 May 2019.

## Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

## Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

# 1. Waiver

## 1.1. Conditions:

- Treatment of rhabdomyosarcoma
- Treatment of non-rhabdomyosarcoma soft tissue sarcoma
- Treatment of Ewing sarcoma family of tumours.

The waiver applies to:

- the paediatric population from birth to less than 2 year of age;
- film-coated tablet, age-appropriate oral formulation, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

# 2. Paediatric Investigation Plan

## 2.1. Conditions:

- Treatment of rhabdomyosarcoma
- Treatment of non-rhabdomyosarcoma soft tissue sarcoma
- Treatment of Ewing sarcoma family of tumours.

### 2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma or Ewing sarcoma family of tumours

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

### 2.1.3. Pharmaceutical form(s)

Film-coated tablet for oral use

Age-appropriate oral formulation

### 2.1.4. Measures

| Area                    | Number of studies | Description                                                                                                         |
|-------------------------|-------------------|---------------------------------------------------------------------------------------------------------------------|
| Quality-related studies | 1                 | <b>Study 1</b><br>Development of an age-appropriate oral formulation to be used in the paediatric clinical studies. |

| Area                 | Number of studies | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Non-clinical studies | 2                 | <p><b>Study 2</b> (G10052)</p> <p>Oral toxicity study in juvenile rats</p> <p><b>Study 3</b> (I10194)</p> <p>Oral toxicokinetic study in juvenile rats</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Clinical studies     | 2                 | <p><b>Study 4</b> (ADVL0815)</p> <p>Single-agent, non-controlled, dose-escalation, open-label, multicentre study to evaluate pharmacokinetics, pharmacodynamics and toxicity of pazopanib in children from 2 years to less than 18 years of age (and young adults) with refractory solid tumours.</p> <p><b>Study 5</b> (VEG116731/ADVL1322)</p> <p>Single-agent, non-controlled, open-label, multi-centre, stratified study to determine the therapeutic activity (response rate and time to progression) of pazopanib in children from 2 years to less than 18 years of age with a recurrent and / or refractory soft tissue sarcoma.</p> <p><i>Study 6</i></p> <p><i>(deleted in procedure EMEA-000601-PIP01-09-M06)</i></p> |

### 3. Follow-up, completion and deferral of PIP

|                                                                                       |                  |
|---------------------------------------------------------------------------------------|------------------|
| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | Yes              |
| Date of completion of the paediatric investigation plan:                              | By November 2019 |
| Deferral for one or more measures contained in the paediatric investigation plan:     | Yes              |



## **Annex II**

### **Information about the authorised medicinal product**

**Condition(s) and authorised indication(s):**

1. Treatment of renal cell carcinoma:

Authorised indication(s):

- Votrient is indicated for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.

2. Treatment of soft tissue sarcoma

Authorised indication(s):

- Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

**Authorised pharmaceutical form(s):**

Film-coated tablet

**Authorised route(s) of administration:**

Oral use